重大事件
即時報告
8-K
2026-07-06
實現生命科學股東會通過授權股數倍增至3億股 所有議案均獲通過
AI 繁中摘要
ACHIEVE LIFE SCIENCES 提交 8-K 申報 📄
申報類型：8-K（重大事件報告）
報告日期：2026年7月2日（股東年會）
提交日期：2026年7月6日
📌 公司：Achieve Life Sciences, Inc.（納斯達克代碼：ACHV），總部位於華盛頓州博塞爾及加拿大溫哥華。
**主要事件：**
1️⃣ 修改公司章程（Item 5.03）
經股東年會批准，公司於7月6日向德拉瓦州州務卿提交章程修正案，將授權普通股股數由1.5億股增加至3億股。董事會早前已通過該修正案，並獲股東投票確認。
2️⃣ 股東年會投票結果（Item 5.07）
- **選舉九名董事**：所有提名人均以高票當選（包括 Jeffrey Farrow、Andrew D. Goldberg、Lucian Iancovici、Chris Martin、Nancy R. Phelan、Aaron Royston、Thomas Sellig、Richard Stewart、Reid Waldman），反對票極少，惟經紀商非投票約2,064萬股。
- **批准會計師事務所**：PricewaterhouseCoopers LLP 獲續聘為2026財年獨立註冊會計師事務所（贊成6,861萬股，反對僅19.8萬股）。
- **高管薪酬諮詢投票**：以非約束性方式通過（贊成4,635萬股，反對61萬股，棄權134.7萬股）。
- **章程修正案（增發授權股份）**：以6,476萬股贊成、341.9萬股反對、76.7萬股棄權獲得通過。
**對投資者的潛在影響 🧐**
- 授權股份倍增（由1.5億增至3億）為公司未來融資、股權激勵或潛在併購提供更大靈活性，但同時可能攤薄現有股東權益。
- 年會所有議案均獲通過，顯示管理層與股東在重大治理事項上取得共識，短期內股權結構變動風險可控。
- 無業績數字或管理層展望披露，本次8-K純粹涉及公司治理及股本架構調整，實際影響需待後續融資或業務進展才能評估。
展開英文正文
8-K --12-31false0000949858BC00009498582026-07-022026-07-020000949858dei:OtherAddressMember2026-07-022026-07-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2026 ACHIEVE LIFE SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 033-80623 95-4343413 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 22722 29th Drive SE, Suite 100 Bothell, WA 98021 1040 West Georgia, Suite 1030 Vancouver, B.C., Canada V6E 4H1 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (604) 210-2217 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of exchange on which registered Common Stock, par value $0.001 per share ACHV The NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On July 6, 2026, following the Annual Meeting of Stockholders (the “Annual Meeting”) of Achieve Life Sciences, Inc. (the “Company”) held on July 2, 2026, the Company filed a certificate of amendment (the “Certificate of Amendment”) to the Company’s third amended certificate of incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to amend the Certificate of Incorporation as contemplated in Proposal 4 (as described in Item 5.07 below). That description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference. The Certificate of Amendment was approved by the Company’s board of directors earlier this year and by the Company’s stockholders at the Annual Meeting. Item 5.07 Submission of Matters to a Vote of Security Holders. The following is a brief description of each matter voted upon at the Annual Meeting and the certified voting results. (1)Election of nine directors to serve until the Company’s next annual meeting or until the directors’ successors are duly elected and qualified: For Withhold Broker Non-Votes Jeffrey Farrow 46,282,223 2,026,985 20,641,395 Andrew D. Goldberg 48,062,586 246,622 20,641,395 Lucian Iancovici 48,072,624 236,584 20,641,395 Chris Martin 48,124,855 184,353 20,641,395 Nancy R. Phelan 46,287,800 2,021,408 20,641,395 Aaron Royston 48,077,240 231,968 20,641,395 Thomas Sellig 47,665,074 644,134 20,641,395 Richard Stewart 47,549,760 759,448 20,641,395 Reid Waldman 48,085,775 223,433 20,641,395 Pursuant to the foregoing votes, the nominees listed above were elected to serve on the Company’s board of directors. (2)Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstain Broker Non-votes 68,612,907 198,133 139,563 — Pursuant to the foregoing vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. (3)Approval, by a non-binding advisory vote, of the compensation paid by the Company to its named executive officers: For Against Abstain Broker Non-votes 46,351,648 610,744 1,346,816 20,641,395 Pursuant to the foregoing non-binding advisory vote, the compensation paid by the Company to its named executive officers was approved. (4)Approval of the Certificate of Amendment to the Certificate of Incorporation to increase the number of the Company's authorized shares of common stock from 150,000,000 shares to 300,000,000 shares: For Against Abstain Broker Non-votes 64,765,256 3,418,706 766,641 — Pursuant to the foregoing vote, the Certificate of Amendment was approved. Item 9.01 Financial Statements and Exhibits. Exhibit Number Exhibit Title or Description 3.1 Certificate of Amendment to Third Amended and Restated Certificate of Incorporation, filed July 6, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ACHIEVE LIFE SCIENCES, INC. Date: July 6, 2026 /s/ Mark Oki Mark Oki Chief Financial Officer (Principal Financial Officer)